Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,007 stopped studies mapped to B-Cell Non-Hodgkin Lymphoma and descendants · 89% state a reason
Over the 1,007 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00183976 | Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT00183989 | Combination Therapy With Fludarabine, Mitoxantrone and Rituximab in Mantle Cell Lymphoma | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT00383565 | FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 2 | terminated | Oct 3, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01309412 | A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma | Phase 1 | terminated | Mar 7, 2011 | Janssen Pharmaceutical K.K. | Protocol was stopped due to the safety issue in Global | Safety / toxicity |
| NCT00293111 | Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory… | Phase 2 | terminated | Feb 17, 2006 | Cephalon | not stated | Not stated |
| NCT00510887 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular… | Phase 2 | terminated | Aug 2, 2007 | Duke University | Low accrual. | Enrollment / accrual |
| NCT00588822 | Rituximab in Treating Patients With Peripheral Neuropathy Caused by Monoclonal Gammopathy… | Phase 2 | terminated | Jan 9, 2008 | Mayo Clinic | Discontinuation due to the high response rate at the 1st stage and slow accrual. | Enrollment / accrual |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00215943 | Phase III Randomized Trial of Thalidomide/Dexamethasone Versus… | Phase 3 | terminated | Sep 22, 2005 | H. Lee Moffitt Cancer Center and Research Institute | Poor accrual, changes in management of newly diagnosed myeloma patients, new drugs/more effective… | Enrollment / accrual |
| NCT01902862 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard… | Phase 2 | terminated | Jul 18, 2013 | Janssen-Cilag G.m.b.H | Recruitment too slow | Enrollment / accrual |
| NCT00441168 | Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin… | Phase 2 | terminated | Feb 28, 2007 | Janssen-Cilag International NV | TRIAL STOPPED due to a change in standard of care and the required patient numbers could no longer… | Other (stated, no rule matched) |
| NCT00943293 | Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for… | Phase 1 | terminated | Jul 22, 2009 | University of Chicago | Poor accrual; did not enter phase 2 | Enrollment / accrual |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and… | Phase 2 | terminated | Nov 6, 2006 | Genzyme, a Sanofi Company | Insufficient cell mobilization for tandem transplants | Other (stated, no rule matched) |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | Phase 1 | terminated | Nov 9, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or… | Phase 1 / Phase 2 | terminated | Jul 11, 2007 | Gilead Sciences | Unacceptable safety profile | Safety / toxicity |
| NCT00590603 | Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple…(AAV) | Phase 1 | terminated | Jan 10, 2008 | Duke University | Poor accrual - terminated during Phase I; Phase II never started. | Enrollment / accrual |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed…(PREMIER) | Phase 2 | terminated | Mar 29, 2006 | Genzyme, a Sanofi Company | Terminated by sponsor due to low enrollment; see details below | Enrollment / accrual |
| NCT00019708 | Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's… | Phase 1 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Dec 19, 2006 | Bayside Health | Lack of efficacy | Efficacy / futility |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | Phase 2 | terminated | May 12, 2009 | Marshall University | Original Principal Investigator left the institution. | Investigator |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC)… | Phase 2 | withdrawn | May 15, 2013 | The University of Texas Health Science Center at San Antonio | not stated | Not stated |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Aug 7, 2006 | H. Lee Moffitt Cancer Center and Research Institute | Initial Principal Investigator left Moffitt | Investigator |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing… | Phase 2 | terminated | Dec 28, 2011 | Texas Oncology Cancer Center | Insufficient accruals | Enrollment / accrual |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for… | Phase 2 | terminated | Jul 21, 2008 | Janssen-Ortho Inc., Canada | Study stopped due to lagging enrolment. | Enrollment / accrual |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or… | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | Phase 1 / Phase 2 | terminated | Oct 21, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00965861 | SCRI Tissue Testing Registry | — | terminated | Aug 26, 2009 | SCRI Development Innovations, LLC | Replaced by a study with a similar design. | Other (stated, no rule matched) |
| NCT00947388 | Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Phase 1 | terminated | Jul 28, 2009 | Case Comprehensive Cancer Center | No more eligible patients | Other (stated, no rule matched) |
| NCT00514722 | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced… | N/A | terminated | Aug 10, 2007 | University of California, San Francisco | low accrual | Enrollment / accrual |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | Phase 2 | terminated | Oct 18, 2005 | Washington University School of Medicine | No response seen in patients | Other (stated, no rule matched) |
| NCT00513318 | Pilot Study of Reduced-Intensity Umbilical Cord Blood Transplantation in Adult Patients… | — | terminated | Aug 8, 2007 | University of California, San Francisco | Insufficient enrollment to justify keeping open. | Enrollment / accrual |
| NCT00003502 | Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00003505 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00085345 | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or… | Phase 2 | withdrawn | Jun 11, 2004 | Oncotherapeutics | not stated | Not stated |
| NCT00112879 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With… | Phase 2 | withdrawn | Jun 3, 2005 | The Cleveland Clinic | not stated | Not stated |
| NCT00377104 | Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small… | Phase 1 | terminated | Sep 15, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00079443 | FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With… | Phase 2 | terminated | Mar 10, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00609817 | Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma | Phase 1 | terminated | Feb 7, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT00776802 | GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory…(GCS-100LE) | Phase 1 / Phase 2 | withdrawn | Oct 21, 2008 | La Jolla Pharmaceutical Company | Lack of funding | Funding |
| NCT01617213 | Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma(AMM-2011) | Phase 2 | terminated | Jun 12, 2012 | University of Virginia | Study is no longer needed as recent data have answered the primary hypotheses for this study. | Other (stated, no rule matched) |
| NCT00009984 | Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01238146 | Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Nov 10, 2010 | National Cancer Institute (NCI) | No patients accrued. | Enrollment / accrual |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With… | Phase 1 | terminated | Feb 8, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00126191 | Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma | Phase 2 | terminated | Aug 3, 2005 | Dana-Farber Cancer Institute | closed due to slow accrual | Enrollment / accrual |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic… | Phase 1 | terminated | Jul 20, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00968396 | Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts | Phase 2 | withdrawn | Aug 31, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01179490 | Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma | Phase 2 | terminated | Aug 11, 2010 | SymBio Pharmaceuticals | not stated | Not stated |
| NCT01680796 | Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple… | Phase 1 | withdrawn | Sep 7, 2012 | University of Florida | The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily… | Other (stated, no rule matched) |
| NCT00005786 | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia | N/A | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 22, 2014source: clinicaltrials